- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01267409
Mapping and Manipulating the Emotional Territories of the Basal Ganglia in PD Patients
January 12, 2012 updated by: Renana Eitan, Hadassah Medical Organization
Mapping and Manipulating the Emotional Territories of the Subthalamic (STN) Area in Deep Brain Stimulation (DBS) Treated Parkinson Patients
Depressive symptoms of Parkinson's disease (PD) patients are major predictors of their prognosis and quality of life.
Using subthalamic nucleus (STN) deep brain stimulation (DBS) as an antidepressant could be a promising new direction.
Existing methods of adjustment of DBS parameters aim at amelioration of the motor signs and therefore with inactivation of the STN motor territory only.
Although the DBS parameter setting is believed to influence the mental state, there is no data that correlates stimulation parameters with mental state.
The investigators hypothesize that the emotional territories of the STN have distinct electrophysiological properties and that specific stimulation of these emotional territories can influence the mental state and thus treatment with emotionally-adjusted DBS can improve the psychiatric symptoms of PD.
In this project, the investigators intend to map the emotional territories of the STN using neuronal (single units) responses to emotional voices and to identify the emotional spectral signature of the STN single unit activity using spectral analysis and neuronal responses to emotional voices.
The investigators also intend to investigate the emotional processing of PD patients by manipulating the stimulation of the subthalamic area.
The proposed study will combine neural recording, stimulation and psychological tests to shed new light on emotional processing in the basal ganglia, as well as to provide better treatment for PD emotional disorders,
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel
- Recruiting
- Hadassah Medical Organization, Jerusalem, Israel
-
Contact:
- Hadas Lemberg, PhD
- Phone Number: : 00 972 2 6777572
- Email: lhadas@hadassah.org.il
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinically definite PD treated / candidates for treatment with DBS (patients with advanced idiopathic PD who are deemed appropriate for DBS surgery).
- Patients will be included in the study irrespective of whether a diagnosis of major depression (MDD) (mild to moderate but not severe MDD) is fulfilled at baseline. Patients without depression will be monitored in the study for evidence of treatment emergent depression. Patients with depression will be monitored for antidepressant effects of stimulation change.
- Age 40-75 years
- Male or female.
- Competent and willing to give written informed consent
Exclusion Criteria:
- Significant suicidal risk [Hamilton Depression scale item 3 (suicide) >2].
- Comorbidity with any Psychotic Disorder, Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Eating Disorder.
- Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months
- Significant cognitive decline, as measured by Addenbrooke's Cognitive Examination (ACE) and the Frontal Assessment Battery (FAB).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Electrophysiological recording and STN mapping
Time Frame: 24 m
|
Mapping the emotional territories of the STN using neuronal (single units) responses to emotional voices during surgery. Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area during and after the surgery. |
24 m
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Anticipated)
December 1, 2012
Study Completion (Anticipated)
December 1, 2012
Study Registration Dates
First Submitted
December 21, 2010
First Submitted That Met QC Criteria
December 27, 2010
First Posted (Estimate)
December 28, 2010
Study Record Updates
Last Update Posted (Estimate)
January 13, 2012
Last Update Submitted That Met QC Criteria
January 12, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EmotionalPD-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Mission TherapeuticsMichael J. Fox Foundation for Parkinson's Research; Parkinson's UKRecruitingParkinson's Disease (PD) | Early Stage Parkinson's Disease | Mild to Moderate Parkinson's DiseaseUnited Kingdom
Clinical Trials on STN stimulation
-
Zhang JianguoNot yet recruitingPD - Parkinson's DiseaseChina
-
University Hospital TuebingenAbbottCompletedParkinson DiseaseGermany
-
University Hospital TuebingenMedtronicUnknownParkinson's DiseaseGermany, Luxembourg
-
Beijing Tiantan HospitalRecruitingParkinson Disease | Deep Brain StimulationChina
-
University Hospital TuebingenMichael J. Fox Foundation for Parkinson's ResearchUnknownParkinson's Disease | DysphagiaGermany
-
Dennis Turner, M.D.National Institute of Neurological Disorders and Stroke (NINDS); Duke University and other collaboratorsEnrolling by invitation
-
Tsinghua UniversityBeijing Tsinghua Changgeng HospitalRecruitingParkinson Disease | Sleep DisorderChina
-
University of Turin, ItalyCompletedParkinson DiseaseItaly
-
Wuerzburg University HospitalUnknownParkinson Disease | DementiaGermany
-
University of FloridaNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingParkinson Disease, IdiopathicUnited States